Cardiac Pacemakers, Inc.

Ethicon Endo-surgery, Inc.

Ethicon, Gmbh

The General Hospital Corporation

Boston Scientific Neuromodulation Corporation

Cilag International Gmbh

The Johns Hopkins University

Axon Therapies, Inc.

Coridea, LLC

Tamara Colette Baynham

Jason L Harris

Joseph M Pastore

Andrew P Kramer

Allan Charles Shuros

Julio Cesar Spinelli

Richard N Cornelussen

Frits W Prinzen

Ward Y R Vanagt

Rodney W Salo

Yi Zhang

Jihong Qu

Taylor W Aronhalt

Jeffrey Ross

Lee M Kaplan

Nicholas Stylopoulos

Bradley Lawrence Hershey

Anthony R DiUbaldi

Mark Gelfand

Jordi Parramon

Tracee E Eidenschink

James Walden Voegele

Darrell Orvin Wagner

Haris Sih

Jeyakumar Subbaroyan

Imad Libbus

Mark S Ortiz

Bruce H KenKnight

Mark S Zeiner

Roger Noel Hastings

Quan Ni

Scott Thomas Mazar

Yatheendhar D Manicka

Shantha Arcot-Krishnamurthy

Julie A Thompson

Donald Lee Hopper

Abhilash Patangay

Kevin John Stalsberg

Michael A Murray

Howard Levin

David James Cagle

David N Plescia

M Jason Brooke

Shelley Marie Cazares

Thomas Edward Albrecht

Matthew Charles Heidner

Daniel Keith Tomaschko

Richard Fogoros

Zoar Jacob Engelman

Harikrishna Tandri

David James Broman

Michael J Pederson

James Cawthra

Theodore L Stephens

Jacob Crabtree

Ward YR Vanagt

A neuromodulation system and method of providing sub-threshold modulation therapy. Electrical modulation energy is delivered to a target tissue site of the patient at a programmed intensity value, thereby providing therapy to a patient without perception of stimulation. In response to an event, electrical modulation energy is delivered at incrementally increasing intensity values. At least one evoked compound action potential (eCAP) is sensed in a population of neurons at the target tissue site of the patient in response to the delivery of the electrical modulation energy at the incrementally increasing intensity values. One of the incrementally increased intensity values is selected based on the sensed eCAP(s). A decreased intensity value is automatically computed as a function of the selected intensity value. Electrical modulation energy is delivered to the target tissue site of the patient at the computed intensity value, thereby providing sub-threshold therapy to the patient.

Systems and methods of providing modulation therapy without patient-perception of stimulation

Methods and devices are provided for activating brown adipose tissue (BAT) using electrical energy. In general, the methods and devices can facilitate activation of BAT to increase thermogenesis. The BAT can be activated by applying an electrical signal thereto that can be configured to target sympathetic nerves that can directly innervate the BAT. The electrical signal can be configured to target the sympathetic nerves using fiber diameter selectivity. In other words, the electrical signal can be configured to activate nerve fibers having a first diameter without activating nerve fibers having diameters different than the first diameter. Sympathetic nerves include postganglionic unmyelinated, small diameter fibers, while parasympathetic nerves that can directly innervate BAT include preganglionic myelinated, larger diameter fibers. The electrical signal can be configured to target and activate the postganglionic unmyelinated, small diameter fibers without activating the preganglionic myelinated, larger diameter fibers.

Methods and devices for activating brown adipose tissue using electrical energy

Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and/or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.

Methods and devices are provided for inhibiting nerves when activating brown adipose tissue (BAT). In general, a first nerve type (e.g., sympathetic nerves) innervating BAT can be activated while at least one other nerve type (e.g., parasympathetic nerves and/or sensory nerves) innervating BAT is being suppressed. A first neuromodulator (e.g., an electrical signal, a chemical, a light, cooling, etc.) can be applied to activate the first nerve type, and a second neuromodulator can be applied to inhibit the at least one other nerve type. In this way, parasympathetic nerves and/or sensory nerves innervating BAT can be inhibited when activating sympathetic nerves innervating BAT.

Methods and devices for inhibiting nerves when activating brown adipose tissue

Methods and devices for treating patients having cardiopulmonary disease such as cardiac arrhythmias, ventricular arrhythmias, pulmonary hypertension, or heart failure comprising a tracheal approach. The method includes ablating a deep cardiac plexus of a patient by advancing an treatment apparatus into a trachea of the patient, extending an ablative energy delivery element of the treatment apparatus through a wall of the trachea at a level of the trachea proximate a tracheal bifurcation, positioning the ablative energy delivery element at a target space between the trachea, an aorta and a pulmonary artery, and ablating, by the ablative energy delivery element, tissue within the target space to substantially disable the deep cardiac plexus.

Method and apparatus to treat cardiopulmonary disease

A system for use during revascularization includes a catheter having an adjustable balloon for delivery a stent, one or more pacing electrodes for delivering one or more pacing pulses to a patient's heart, and a pacemaker configured to generate the one or more pacing pulses to be delivered to the heart via the one or more pacing electrodes. The one or more pacing pulses are delivered at a rate substantially higher than the patient's intrinsic heart rate without being synchronized to the patient's intrinsic cardiac contractions, and are delivered before, during, or after an ischemic event to prevent or reduce cardiac injury.

Method and apparatus for pacing during revascularization

A method for treating a disorder of a patient. The method comprises transcutaneously delivering electrical energy to a targeted tissue site at a frequency of at least 50 KHz, thereby treating the disorder.

Electrical stimulation for treating neurological disorders

Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.

Devices and methods for treatment of heart failure via electrical modulation of a splanchnic nerve

Growing community of inventors

Piscataway, NJ, United States of America

Tamara Colette Baynham